Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Dexmedetomidine for Sedated ABR in Children
NCT03530371Phase 3Completed
- Sponsor
- Fondation Lenval
- Start
- May 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dexmedetomidine in hearing loss, sponsored by Fondation Lenval. Primary endpoint: quality of diagnostic. Started May 2019; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
hearing loss
Beyond the preview
Go deeper on NCT03530371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03530371.